Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHr1 antagonists

Quinoline-derivatives as privileged scaffolds for medicinal and pharmaceutical chemists: A comprehensive review

The quinoline scaffolds are privileged for their numerous biological activities in the pharmaceutical field. This moiety constitutes a well-known space in several marketed preparations. The quinoline scaffolds gained attention in modern days being an important chemical moiety in the identification, designing, and synthesis of novel potent derivatives. The current review is developed to shine the light on critical and significant insights on the quinoline derivatives possessing diverse biological activities such as analgesic, anti-inflammatory, antialzheimer, anti-convulsant, anti-oxidant, antimicrobial, anti-cancer activities and so on. A detailed summary of quinoline ring from its origin to the recent advancements regarding its synthesis, green chemistry approaches, patented methods, and its marketed drugs is presented in the review. We attempted to review the literature compiling the critical information that has potential to encourage fellow researchers and scientists for the design and development of quinoline scaffold based active molecules that have improved therapeutic performance along with profound pharmacological properties.

A versatile way for the synthesis of monomethylamines by reduction of N-substituted carbonylimidazoles with the NaBH4/I2 system

An economical and versatile protocol for the one-pot synthesis of monomethylamines by reduction of N-substituted carbonylimidazoles with NaBH₄/I₂ in THF at reflux temperature is described. This method used no special catalyst and various monomethylamines can be easily obtained in moderate to good yields from a wide range of raw materials including amines (primary amines and secondary amines), carboxylic acids and isocyanates. Besides, an interesting reduction selectivity was observed. Exploration of the reaction process shows that it undergoes a two-step pathway via a formamide intermediate and the reduction of the formamide intermediate to monomethylamine as the rate-determining step. This work can contribute significantly expanding the applications of N-substituted carbonylimidazoles.

Greening Solid-Phase Organic Synthesis: Environmentally Conscious Synthesis of Pharmaceutically Relevant Privileged Structures 5,6-Dihydropyridin-2(1H)-ones and Quinolin-2(1H)-ones

Solid-phase organic synthesis (SPOS) is a very efficient methodology for the synthesis of diverse organic molecules, particularly exploited in drug discovery. Here, we present the transformation of the traditional SPOS to an eco-friendlier methodology on examples of pharmacologically relevant privileged structures 5,6-dihydropyridin-2(1H)-ones and quinolin-2(1H)-ones. The green approach is primarily based on the utilization of environmentally friendly solvent 2-MeTHF in all steps of the synthesis. Target heterocycles were synthesized by extending our previously published synthesis of five-membered tetramic acid analogues to six-membered cycles. The crucial step of the synthesis is cyclization via nonclassical Wittig olefination of resin-bound esters. Traditional and green protocols provided comparable results with respect to purity and yield of products, thus opening the way for greener access to a variety of diverse heterocycles.

Recyclable Keggin Heteropolyacids as an Environmentally Benign Catalyst for the Synthesis of New 2-Benzoylamino-N-phenyl-benzamide Derivatives under Microwave Irradiations at Solvent-Free Conditions and the Evaluation of Biological Activity

2-Benzoylamino-N-phenyl-benzamide derivatives (5a–h) were prepared from 2-phenyl-3,1-(4H)-benzoxazin-4-one 3 and substituted anilines 4a–h in the presence of a Keggin-type heteropolyacids series (H₃PW₁₂O₄₀·13H₂O; H₄SiW₁₂O₄₀·13H₂O; H₄SiMo₁₂O₄₀·13H₂O; and H₃PMo₁₂O₄₀·13H₂O) as catalysts without solvent and under microwave irradiation. We found that the use of H₃PW₁₂O₄₀·13H₂O acid coupled to microwave irradiation allowed obtaining a high-yielding reaction with a short time. The compound structures were established by ¹H-NMR and ¹³C-NMR. The antibacterial and antifungal activities of the synthesized compounds exhibited an inhibition of the growth of bacteria and fungi.

Computational Tool for Fast in silico Evaluation of hERG K+ Channel Affinity

The development of a novel comprehensive approach for the prediction of hERG activity is herein presented. Software Phase has been used to derive a 3D-QSAR model, employing as alignment rule a common pharmacophore built on a subset of 22 highly active compounds (threshold Ki: 50 nM) against hERG K⁺ channel. Five features comprised the pharmacophore: two aromatic rings (R₁ and R₂), one hydrogen-bond acceptor (A), one hydrophobic site (H), and one positive ionizable function (P). The sequential 3D-QSAR model developed with a set of 421 compounds (randomly divided in training and test set) yielded a test set (Q²) = 0.802 and proved to be predictive with respect to an external test set of 309 compounds that were not used to generate the model (rext_ts2 = 0.860). Furthermore, the model was submitted to an in silico validation for assessing the reliability of the approach, by applying a decoys set, evaluating the Güner and Henry score (GH) and the Enrichment Factor (EF), and by using the ROC curve analysis. The outcome demonstrated the high predictive power of the inclusive 3D-QSAR model developed for the hERG K⁺ channel blockers, confirming the fundamental validity of the chosen approach for obtaining a fast proprietary cardiotoxicity predictive tool to be employed for rationally designing compounds with reduced hERG K⁺ channel activity at the early steps of the drug discovery trajectory.

The Therapeutic Potential of hERG1 K+ Channels for Treating Cancer and Cardiac Arrhythmias

hERG potassium channels present pharmacologists and medicinal chemists with a dilemma. On the one hand hERG is a major reason for drugs being withdrawn from the market because of drug induced long QT syndrome and the associated risk of inducing sudden cardiac death, and yet hERG blockers are still widely used in the clinic to treat cardiac arrhythmias. Moreover, in the last decade overwhelming evidence has been provided that hERG channels are aberrantly expressed in cancer cells and that they contribute to tumour cell proliferation, resistance to apoptosis, and neoangiogenesis. Here we provide an overview of the properties of hERG channels and their role in excitable cells of the heart and nervous system as well as in cancer. We consider the therapeutic potential of hERG, not only with regard to the negative impact due to drug induced long QT syndrome, but also its future potential as a treatment in the fight against cancer.

Medicinal Chemistry Challenges in CNS Drug Discovery

The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to avoid injury from external insults and toxins. Penetrating the blood-brain barrier (BBB) to achieve the drug concentrations required for efficacious target receptor occupancy in the brain region of interest is a unique and significant challenge facing medicinal chemists working on CNS targets. Prospective design of molecules with optimal brain exposure and safety profile requires in-depth understanding of the fundamental relationships between physicochemical properties and in vitro and in vivo outcomes. Following from the now widely accepted “rule of five” guidelines for the design of oral drugs, the physicochemical properties for brain penetration have been extensively studied in an effort to define the characteristics of successful CNS drug candidates. Several key physicochemical properties have been identified that influence the rate of brain permeability and extent of brain penetration, including H-bonding potential, molecular weight, lipophilicity, polar surface area (PSA), ionization state and rotatable bond count. The ability to process this information effectively and engage in multi-parameter prospective design ultimately determines the success in delivering high-quality drug candidates that are suitable robustly to test hypotheses in the clinic and have good probability of reaching the market. This chapter focuses on the medicinal chemistry aspects of drug candidate optimization particular to the CNS therapeutic area, such as crossing the blood-brain barrier (BBB), as well as safety-related issues frequently challenging CNS programs such as hERG selectivity and phospholipidosis.

Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor

This Letter describes the continued optimization of the MLPCN probe molecule ML071. After introducing numerous cyclic constraints and novel substitutions throughout the parent structure, we produced a number of more highly potent agonists of the M(1) mACh receptor. While many novel agonists demonstrated a promising ability to increase soluble APPα release, further characterization indicated they may be functioning as bitopic agonists. These results and the implications of a bitopic mode of action are presented.

Efficient synthesis and identification of novel propane-1,3-diamino bridged CCR5 antagonists with variation on the basic center carrier

By employing pharmacophore-based design and the privileged fragments reassembly, a series of piperidine-/tropane-/piperazine-bridged CCR5 antagonists were designed and synthesized via an efficient convergent synthesis strategy, with focus on the optimal choice of the basic center carrier structure. Significantly, the 4-amino-4-methylpiperidine bridged 1-acyl-1,3-propanediamine compounds were identified as a new class of nanomolar CCR5 antagonists, providing an efficient approach and novel scaffolds for further development of potent CCR5 inhibitors.

Melanin-Concentrating Hormone Receptor-1 Antagonists as Antiobesity Therapeutics

There is compelling genetic and pharmacologic evidence to indicate that melanin-concentrating hormone receptor-1 (MCHR1) signaling is involved in the regulation of food intake and energy expenditure. The medical need for novel therapies to treat obesity and related metabolic disorders has led to a great deal of interest by pharmaceutical companies in the discovery of MCHR1 antagonists. Recent publications describing preclinical studies have demonstrated that small-molecule MCHR1 antagonists decrease food intake, bodyweight, and adiposity in rodent models of obesity. Results from ongoing early-stage clinical trials with MCHR1 antagonists are eagerly awaited, as is the movement of other MCHR1 antagonists into the clinic.